2023 World Baseball Classic Begins, Taiwan Excellence Supports
8.3.2023 11:10:00 EET | Business Wire | Press release
The World Baseball Classic (WBC) is returning to Taiwan, after a ten-year hiatus, for the qualifying rounds. The tournament will feature teams from Taiwan, the Netherlands, Cuba, Italy, and Panama, who will showcase their skills starting on March 8th. As the host country for the A-group preliminaries, Taiwan extends a warm welcome to the players through enthusiastic fans, fascinating cuisine, and the opportunity to experience the latest Taiwan Excellence awarded technology and lifestyle products.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230311005004/en/
The WBC was postponed for two years due to the impact of COVID-19. With hygiene and safety being top priorities, Major League Baseball (MLB) has adopted stringent standards for the event. The Taiwanese organizers have prepared the world's first indoor wireless rapid antibacterial machine, the AQUECARE T1 Plus sanitizer. This innovative solution has received the Taiwan Excellence Award and will play a vital role in maintaining environmental hygiene throughout the tournament.
Because long-haul flights can cause fatigue among players, posing them a significant challenge, the organizers have provided the world's first AURAI intelligent eye massager in order to facilitate more rapid recovery. This device helps to alleviate eye fatigue, improves sleep quality, and will recharge energy levels for the players. They will also be able to use AROMASE all-in-one purifying gel which contains three different types of herbal extracts. This gel is effective in purifying the body and mind after each training session and competition. Furthermore, we prioritize environmental sustainability, and have prepared O’right toothpaste, a revolutionary toothpaste made from sustainable tree powder as a grinding agent. This toothpaste is certified by USDA Biobased.
Taiwan is well-known as a technology island, and its consumer electronics and ICT products have gained recognition from consumers worldwide. So, the organizers are providing the players with another Taiwan Excellence awarded product, the PX 4K HDR Wireless Presentation Receiver. This product supports 4K HDR wireless transmission and provides a convenient 4K wireless projection function from mobile phones and laptops to televisions, enabling players to relax and enjoy different forms of entertainment when away from the intensity of competition.
As a souvenir for players from around the world, the Qubii auto-backup device has been chosen. This is a hand-sized device that automatically backs up photos, videos, contacts, and other content while your phone is charging. This device allows players to easily back up precious game data and memories when they run out of phone storage.
Taiwan is making every effort to provide a comfortable and safe environment with the very best professional equipment, in the hopes that the teams will enjoy their stay in Taiwan and maximize their performance in the WBC. Taiwan Excellence, a globally recognized symbol of product quality and innovative design, plays an important role in this commitment. Taiwan Excellence will continue to discover and introduce more high-quality Taiwanese products, featuring innovative breakthroughs to the world, enriching the lives of people everywhere.
For more information, please visit our website https://www.taiwanexcellence.org/en
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230311005004/en/
Contact information
Brain Lee, TAITRA
brianlee@taitra.org.tw
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
